- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06603012
Behavioral Intervention for Lifestyle Physical Activity in Parkinson's Disease (LifePD)
June 2, 2026 updated by: Robert W Motl, University of Illinois at Chicago
The investigators propose a Stage-I randomized controlled trial (RCT) of a remotely-delivered, 16-week social-cognitive theory-based behavioral intervention focusing on combined exercise (aerobic and resistance) training for yielding increases in device-measured physical activity and improvements in cognitive function, symptoms, and quality of life (QOL), and social-cognitive theory (SCT) outcomes among physically inactive persons with Parkinson's disease (PD).
Participants (N=50) will be randomly assigned into exercise training (combined aerobic and resistance exercise) condition or active control (flexibility and stretching) condition.
The 16-week intervention will be delivered and monitored remotely within a participant's home/community and supported by Zoom-based chats guided by SCT via a behavioral coach.
Participants will receive training materials (e.g., prescriptive manual and exercise equipment), one-on-one coaching, action-planning via calendars, self-monitoring via logs, and SCT-based newsletters.
The investigators hypothesize that the home-based exercise intervention will yield improvements in cognitive, symptomatic, and QOL outcomes.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
Parkinson's disease (PD) is a neurodegenerative disorder of the dopamine-producing nerve cells in the basal ganglia, and age is a primary risk factor for PD.
Cognitive impairment is prevalent, disabling, and poorly managed among the 1 million adults living with PD in the United States.
Indeed, cognitive impairment begins early in PD, and dementia develops in 80% of persons with PD.
Cognitive impairment is further associated with worse fatigue, depression, anxiety, pain, and quality of life (QOL) in PD.
Those observations underscore the importance of identifying efficacious approaches for managing cognitive impairment and its consequences, and promoting additional health benefits among those with PD.
To date, researchers have examined the benefits of supervised, structured exercise training for managing outcomes of PD, but this approach has clear barriers associated with travel, transportation, and participation (i.e., loss of driving ability, social isolation, and lack of community integration) that are common in PD.
The investigators believe that there is merit in the promotion of physical activity for managing cognitive dysfunction and other symptom and QOL outcomes in PD.
The investigators offer a novel and innovative approach for promotion of physical activity in PD based on their extensive experiences from Phase I, II, and III randomized controlled trials (RCTs).
Those RCTs indicate that the remotely-delivered, social-cognitive theory-based behavioral intervention has successfully increased self-reported and device-measured physical activity in persons with multiple sclerosis (MS).
This approach has further resulted in improvements in cognition and walking outcomes, symptoms of fatigue, depression, anxiety, and pain, and QOL among persons with MS.
The investigators leverage their experiences and preliminary results in MS, and propose a Stage-I RCT that examines the feasibility and efficacy of a remotely-delivered, theory-based behavioral intervention focusing on combined exercise (aerobic and resistance) training for yielding immediate improvements in device-measured physical activity (primary outcome) among persons with PD who are physically inactive.
The investigators further examine the efficacy of this behavioral intervention for improvements in cognitive function, symptoms, and QOL (secondary outcomes).
The proposed study, if successful, will provide experiences and pilot data necessary for the design of a subsequent Stage-II RCT that examines the efficacy of the behavioral intervention for immediate and sustained improvements of outcomes in an appropriately-powered and clearly-demarcated sample of adults with PD (i.e., those 50+ years of age who are prescreened for cognitive impairment).
This line of research may yield "real-world" guidelines for physical activity that can be implemented for the treatment of cognitive dysfunction and other outcomes in PD.
Such an opportunity for rehabilitation of cognitive function using an approach with broad reach and scalability is paramount considering the prevalent, disabling, and poorly managed nature of cognitive impairment in PD and limited efficacious resources for its treatment.
Study Type
Interventional
Enrollment (Estimated)
50
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Brenda Jeng, PhD
- Phone Number: 312-996-6615
- Email: enrl@uic.edu
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- University of Illinois at Chicago
-
Contact:
- Robert Motl, PhD
- Phone Number: 312-413-0319
- Email: robmotl@uic.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- confirmed diagnosis of PD
- Internet and email access
- willingness to complete the cognitive assessments and questionnaires, wear the accelerometer, and undergo randomization
- insufficient physical activity (i.e., not meeting current physical activity guidelines) based on a health contribution score of less than 14 units from the Godin Leisure-Time Exercise Questionnaire
- self-reported ability to ambulate without assistance
- age of 50+ years
- English as a primary language
- asymptomatic (i.e., one or fewer affirmatives on the Physical Activity Readiness Questionnaire [PAR-Q]) or physician approval for undertaking exercise training for those with 2 or more affirmatives on the PAR-Q
Exclusion Criteria:
- above inclusion criteria not met
- moderate or high risk of contraindications for possible injury or death when undertaking strenuous or maximal exercise using the PAR-Q
- severe cognitive impairment that might preclude compliance with the conditions based on a modified Telephone Interview for Cognitive Status (TICS-M) score of less than 18
- normal cognitive impairment based on the Montreal Cognitive Assessment (MoCA) score of 26 or more for avoiding ceiling effects involving change in cognitive function
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: GET Up PD
Remotely-coached/guided, home-based program delivered using telerehabilitation focusing on aerobic fitness and muscle strength as a mode of training
|
|
|
Active Comparator: Stretching and Flexibility
Remotely-coached/guided, home-based program delivered using telerehabilitation focusing on stretching and range of motion as the mode of training
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Physical Activity
Time Frame: Changes in time spent in light physical activity from Baseline (pre-intervention) to after 16 weeks (post-intervention)
|
ActiGraph Gt3X+ accelerometer; minutes spent in light physical activity per day
|
Changes in time spent in light physical activity from Baseline (pre-intervention) to after 16 weeks (post-intervention)
|
|
Physical Activity
Time Frame: Changes in time spent in moderate-to-vigorous physical activity from Baseline (pre-intervention) to after 16 weeks (post-intervention)
|
ActiGraph Gt3X+ accelerometer; minutes spent in moderate-to-vigorous physical activity per day
|
Changes in time spent in moderate-to-vigorous physical activity from Baseline (pre-intervention) to after 16 weeks (post-intervention)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cognitive Function
Time Frame: Changes in SCOPA-Cog Baseline (pre-intervention) to after 16 weeks (post-intervention)
|
SCales for Outcomes in PArkinson's disease - COGnition (SCOPA-Cog); scores range between 0-43, higher scores indicate better cognitive function
|
Changes in SCOPA-Cog Baseline (pre-intervention) to after 16 weeks (post-intervention)
|
|
Fatigue Severity
Time Frame: Changes in fatigue severity scores from Baseline (pre-intervention) to after 16 weeks (post-intervention)
|
Fatigue Severity Scale (FSS); scores range between 1 (min) and 7 (max), higher scores reflect greater fatigue severity
|
Changes in fatigue severity scores from Baseline (pre-intervention) to after 16 weeks (post-intervention)
|
|
Depressive Symptoms
Time Frame: Changes in depressive symptoms scores from Baseline (pre-intervention) to after 16 weeks (post-intervention)
|
Hospital Anxiety and Depression Scale (HADS); scores range between 0 (min) and 21 (max), higher scores reflect greater frequency of anxiety and depressive symptoms
|
Changes in depressive symptoms scores from Baseline (pre-intervention) to after 16 weeks (post-intervention)
|
|
Fatigue Impact
Time Frame: Changes in fatigue impact scores from Baseline (pre-intervention) to after 16 weeks (post-intervention)
|
Modified Fatigue Impact Scale (MFIS); scores range between 0 (min) and 84 (max), higher scores reflect a greater impact of fatigue on daily life
|
Changes in fatigue impact scores from Baseline (pre-intervention) to after 16 weeks (post-intervention)
|
|
Anxiety
Time Frame: Changes in anxiety scores from Baseline (pre-intervention) to after 16 weeks (post-intervention
|
Hospital Anxiety and Depression Scale (HADS); scores range between 0 (min) and 21 (max), higher scores reflect greater frequency of anxiety and depressive symptoms
|
Changes in anxiety scores from Baseline (pre-intervention) to after 16 weeks (post-intervention
|
|
Perceived Pain
Time Frame: Changes in perceived pain from Baseline (pre-intervention) to after 16 weeks (post-intervention)
|
Short-form McGill Pain Questionnaire (SF-MPQ); scores range between 0 and 45, higher scores indicate more perceived pain
|
Changes in perceived pain from Baseline (pre-intervention) to after 16 weeks (post-intervention)
|
|
Health-related Quality of Life
Time Frame: Changes in SF-36 scores from Baseline (pre-intervention), after 16 weeks (post-intervention)
|
Short Form Health Status Survey (SF-36); scores range between 0 (min) and 100 (max), higher scores indicate better physical and mental aspects of quality of life
|
Changes in SF-36 scores from Baseline (pre-intervention), after 16 weeks (post-intervention)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Social Cognitive Theory
Time Frame: Changes in exercise self-efficacy from Baseline (pre-intervention) to after 16 weeks (post-intervention)
|
Exercise Self-Efficacy Scale (EXSE); scores range between 0 (not at all confident) to 100 (completely confident), higher scores indicate more self-efficacy
|
Changes in exercise self-efficacy from Baseline (pre-intervention) to after 16 weeks (post-intervention)
|
|
Social Cognitive Theory
Time Frame: Changes in barriers for self-efficacy from Baseline (pre-intervention) to after 16 weeks (post-intervention)
|
Barriers for Self-Efficacy Scale (BARSE); scores range between 0 (Not at all confident) to 100 (Completely confident), higher scores indicate more self-efficacy to overcome barriers to exercise
|
Changes in barriers for self-efficacy from Baseline (pre-intervention) to after 16 weeks (post-intervention)
|
|
Social Cognitive Theory
Time Frame: Changes in exercise goal setting from Baseline (pre-intervention) to after 16 weeks (post-intervention)
|
Exercise Goal Setting (EGS); scores range between 0 and 50, higher scores indicate stronger tendency to set goals
|
Changes in exercise goal setting from Baseline (pre-intervention) to after 16 weeks (post-intervention)
|
|
Social Cognitive Theory
Time Frame: Changes in exercise planning from Baseline (pre-intervention) to after 16 weeks (post-intervention)
|
Exercise Planning (EPS); scores range between 0 and 50, higher scores indicate stronger tendency to make plans to engage in exercise and physical activity
|
Changes in exercise planning from Baseline (pre-intervention) to after 16 weeks (post-intervention)
|
|
Social Cognitive Theory
Time Frame: Changes in outcome expectations from Baseline (pre-intervention) to after 16 weeks (post-intervention)
|
Multidimensional Outcome Expectations for Exercise Scale (MOEES), higher scores indicate greater perceptions of positive benefits of regular exercise and physical activity
|
Changes in outcome expectations from Baseline (pre-intervention) to after 16 weeks (post-intervention)
|
|
Social Cognitive Theory
Time Frame: Changes in perceived social support for self-efficacy from Baseline (pre-intervention) to after 16 weeks (post-intervention)
|
Social Provisions Scale (SPS); scores range between 6 and 24, higher scores indicate more perceived support
|
Changes in perceived social support for self-efficacy from Baseline (pre-intervention) to after 16 weeks (post-intervention)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Robert Motl, PhD, University of Illinois at Chicago
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
August 1, 2026
Primary Completion (Estimated)
August 1, 2027
Study Completion (Estimated)
August 1, 2027
Study Registration Dates
First Submitted
September 16, 2024
First Submitted That Met QC Criteria
September 16, 2024
First Posted (Actual)
September 19, 2024
Study Record Updates
Last Update Posted (Actual)
June 4, 2026
Last Update Submitted That Met QC Criteria
June 2, 2026
Last Verified
June 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY2024-1038
- P30AG022849 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease (PD)
-
Bezmialem Vakif UniversityRecruitingParkinson Disease | Parkinson | Parkinson Disease (PD) | PARKINSON DISEASE (Disorder) | Parkinson s DiseaseTurkey (Türkiye)
-
University of FloridaCompletedParkinson Disease (PD)United States
-
Haukeland University HospitalUniversity of Bergen; SPARK NSRecruitingParkinson Disease (PD) | Parkinson s DiseaseNorway
-
Royan InstituteShiraz University of Medical Sciences; Iran University of Medical Sciences; Royan...RecruitingParkinson Disease (PD)Iran
-
Marmara UniversityRecruiting
-
Northumbria UniversityDANU Sports LtdRecruitingParkinson Disease(PD)United Kingdom
-
Liaoning Medical Diagnosis and Treatment Technology...Not yet recruitingMovement Disorders | Neurodegenerative Diseases | Parkinson Disease (PD)
-
Chang Gung UniversityCompleted
-
Duke UniversityMedical University of South Carolina; Massachusetts General Hospital; Mayo Clinic and other collaboratorsNot yet recruitingGut Microbiota | Gut Microbiome | Parkinson Disease (PD) | PARKINSON DISEASE (Disorder) | Prodromal Parkinsons DiseaseUnited States
-
Kanuni Sultan Suleyman Training and Research HospitalRecruitingParkinson Disease (PD)Turkey (Türkiye)
Clinical Trials on GET Up PD
-
West Park Healthcare CentreCompleted
-
University of Texas Southwestern Medical CenterChildren's Medical Center DallasRecruitingPediatric Obesity | Pediatric Overweight | Overweight , ObesityUnited States
-
Montefiore Medical CenterNational Institute on Drug Abuse (NIDA)CompletedHepatitis C | Substance Use DisordersUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMalignant Solid Neoplasm | Hematopoietic and Lymphatic System NeoplasmUnited States
-
Case Western Reserve UniversityCompleted
-
Ankara Yildirim Beyazıt UniversityCompleted
-
University of California, IrvineCompletedCardiovascular Diseases | Cardiovascular Risk FactorUnited States
-
Centre Henri BecquerelCompletedDiffuse Large B Cell Lymphoma | Grade IIIB Follicular LymphomaFrance
-
Sophiahemmet UniversityThe Swedish Research Council; Göteborg UniversityRecruiting